Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial.

ABSTRACT:

Objective

To assess the incremental cost and cost-effectiveness of continuous and discontinuous regimens of bevacizumab (Avastin) and ranibizumab (Lucentis) for neovascular age-related macular degeneration (nAMD) from a UK National Health Service (NHS) perspective.

Design

A within-trial cost-utility analysis with a 2-year time horizon, based on a multicentre factorial, non-inferiority randomised controlled trial.

Setting

23 hospital ophthalmology clinics.

Participants

610 patients aged ≥50 years with untreated nAMD in the study eye.

Interventions

0.5 mg ranibizumab or 1.25 mg bevacizumab given continuously (monthly) or discontinuously (as-needed) for 2 years.

Main outcome measures

Quality-adjusted life-years (QALYs).

Results

Total 2-year co

SUBMITTER: Dakin HA 

PROVIDER: S-EPMC4120317 | biostudies-literature | 2014 Jul

REPOSITORIES: biostudies-literature